Outlook Therapeutics (FRA:41O) Receivables Turnover : 0.00 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Outlook Therapeutics's Revenue for the three months ended in Dec. 2024 was €0.00 Mil. Outlook Therapeutics's average Accounts Receivable for the three months ended in Dec. 2024 was €0.00 Mil.

Outlook Therapeutics Receivables Turnover Historical Data

The historical data trend for Outlook Therapeutics's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Receivables Turnover Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Receivables Turnover

Get a 7-Day Free Trial

Outlook Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Receivables Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Outlook Therapeutics's Receivables Turnover

For the Biotechnology subindustry, Outlook Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Outlook Therapeutics Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Outlook Therapeutics's Receivables Turnover for the fiscal year that ended in Sep. 2024 is calculated as

	Receivables Turnover (A: Sep. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Sep. 2024 )	/ (	(Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Sep. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Outlook Therapeutics's Receivables Turnover for the quarter that ended in Dec. 2024 is calculated as

	Receivables Turnover (Q: Dec. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2024 )	/ (	(Accounts Receivable (Q: Sep. 2024 )	+	Accounts Receivable (Q: Dec. 2024 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Outlook Therapeutics (FRA:41O) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Outlook Therapeutics Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

OTLK:USA

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines